Arcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, Arcutis Biotherapeutics Inc. announced that ZORYVE (roflumilast) cream 0.15% received a strong recommendation in the American Academy of Dermatology’s/AAD’s focused guideline update for the management of adult atopic dermatitis/AD.

This recommendation highlights ZORYVE’s proven efficacy, safety, and tolerability as a next-gen and steroid-free topical phosphodiesterase-4 (PDE4) inhibitor. Among newly evaluated branded topical therapies, ZORYVE is the only one with a strong recommendation for adults with mild to moderate AD in this updated guideline. It’s the first FDA-approved branded topical PDE4 inhibitor specifically indicated for mild to moderate atopic dermatitis in patients 6 years of age and older.

A biotechnologist working in a laboratory, examining the effects of a Janus Kinase type 1 inhibitor on plaque psoriasis.

Atopic dermatitis is the most common type of eczema and affects ~16.5 million adults and 9.6 million children in the US. The AAD’s strong recommendation guides clinicians and patients toward treatments that offer clinically meaningful improvements in disease severity while being safe and well-tolerated for long-term use. The update integrates newly FDA-approved topical and biologic therapies into existing guidelines.

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is a biopharmaceutical company that develops and commercializes treatments for dermatological diseases.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.